Back to Treatments

Treatment

Venetoclax + Obinutuzumab

1
Conditions
45
Trials
6,000
Participants
38%
Average Safety

Condition Evidence

Chronic lymphoid leukemia

45 trials · 6,000 participants

92% effectiveness · 38% safety
Venetoclax + Obinutuzumab | DFDA